SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)--LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

�With more than 25 years of experience in the industry, including a robust track record of leading successful drug launches, we are confident that Pascal will play a critical role in developing our China business strategy, building upon our China operations and the infrastructure to develop and commercialize our products,� said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman, LianBio. �We are proud to have Pascal join our team as we continue to work diligently to bring innovative medicines to patients in the years to come.�

Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair. He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.

Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China. In this capacity, he oversaw a more than 700-person China Oncology BU team and was responsible for the group�s P&L and organizational development. Prior to Lilly, Mr. Qian held roles at Novartis from 2012 until 2018, ultimately serving as Executive Director, BU Head of Solid Tumor at Novartis Oncology. From 2005 until 2012, he served in several key roles of increasing responsibility at Pfizer, including Business Liaison Head, Global Clinical Development and Medical Affairs, and China Oncology Business Unit Head.

Mr. Qian graduated from Shanghai Jiaotong University Medical Institute (Shanghai 2nd Medical University).

About LianBio

LianBio�s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and other major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit www.lianbio.com.

Contacts

For investor inquiries, please contact:

Elizabeth Anderson, VP Communications and Investor Relations

E: [email protected]
T: +1 646 655 8390

For media inquiries, please contact:

Tyler Gagnon, CanaleComm

E: [email protected]
T: +1 508 904 9446